01—Abstract
Summary
Summary of the 10-Q filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported a modest increase in total revenues for the first quarter of 2025, reaching $10.36 billiona, up slightly from $10.34 billion in the prior year period.
This growth was driven by positive contributions from the Analytical Instruments, Specialty Diagnostics, and Life Sciences Solutions segments, partially offset by a decline in the Laboratory Products and Biopharma Services segment, influenced by the moderation of COVID-19 related revenues. The company demonstrated resilience with a 15% increase in GAAP diluted earnings per share to $3.98b, while adjusted diluted EPS saw a 1% rise to $5.15. Key drivers for earnings improvement included strong productivity gains and a favorable tax benefit from a domestication transaction, which helped to offset unfavorable business mix and strategic investments.
From a balance sheet perspective, total assets grew to $99.04 billionc, supported by robust cash and cash equivalents of $4.13 billion. The company maintained a strong liquidity position, with no outstanding borrowings under its $5 billion revolving credit facility as of quarter-end.
Thermo Fisher continued its capital deployment strategy, repurchasing $2.00 billiond of its common stock and paying $0.15 billion in dividends during the quarter. The company also announced a significant pending acquisition of Solventum Corporation’s Purification & Filtration business for approximately $4.1 billion, expected to close by year-end 2025, which is poised to strengthen its Life Sciences Solutions segment.
02—Key points
Key Highlights
- Total revenues for the first quarter of 2025 were $10.36 billion, a slight increase of 0% year-over-year, with organic revenue growth of 1%.
- GAAP diluted earnings per share increased by 15% to $3.98, and adjusted diluted EPS grew by 1% to $5.15, reflecting improved operational efficiency and a favorable tax impact.
- The company generated strong operating cash flow of $723 million, though free cash flow decreased to $373 million compared to $908 million in the prior year, primarily due to increased capital expenditures and working capital investments.
- Total assets reached $99.04 billion, with cash and cash equivalents at $4.13 billion, indicating a healthy liquidity position.
- Thermo Fisher continues to actively manage its capital structure, repurchasing $2.00 billion of its common stock and paying $0.15 billion in dividends.
- A significant pending acquisition of Solventum Corporation’s Purification & Filtration business for approximately $4.1 billion was announced, expected to close by the end of 2025.
- Restructuring and other costs increased to $98 million, primarily related to headcount reductions and facility consolidations aimed at streamlining operations.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 2, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $10.36B$10.35B | +0.2% |
| R&D Expenses | $342.00M$331.00M | +3.3% |
| SG&A Expenses | $2.08B$2.18B | −4.8% |
| Operating Expenses | $8.65B$8.68B | −0.4% |
| Operating Income | $1.72B$1.66B | +3.2% |
| Net Income | $1.51B$1.33B | +13.5% |
| EPS (Basic) | $3.99$3.47 | +15.0% |
| EPS (Diluted) | $3.98$3.46 | +15.0% |
| Shares Outstanding (Basic) | 378.00M382.00M | −1.0% |
| Shares Outstanding (Diluted) | 379.00M384.00M | −1.3% |
05—Questions
Frequently Asked Questions
What was the revenue performance in the first quarter of 2025?
Thermo Fisher Scientific reported total revenues of $10.36 billion for the first quarter of 2025, a marginal increase of 0% compared to the same period last year. Organic revenue growth, excluding the impact of acquisitions, divestitures, and currency translation, was 1%.
How did the company's profitability fare in the quarter?
Profitability showed improvement, with GAAP diluted earnings per share rising 15% to $3.98. Adjusted diluted earnings per share also saw an increase of 1%, reaching $5.15. This performance was supported by strong productivity improvements and a notable tax benefit related to a domestication transaction.
What is the company's cash flow situation and capital allocation strategy?
The company generated $723 million in cash from operating activities. Free cash flow was $373 million, a decrease from the prior year, largely due to increased investments in property, plant, and equipment. Thermo Fisher continued its capital allocation strategy by repurchasing $2.00 billion of its common stock and paying $0.15 billion in dividends.
Are there any significant acquisitions or strategic initiatives underway?
Yes, Thermo Fisher announced a pending acquisition of Solventum Corporation’s Purification & Filtration business for approximately $4.1 billion in cash, expected to close by the end of 2025. This acquisition is anticipated to enhance the Life Sciences Solutions segment. Additionally, the company incurred $98 million in restructuring and other costs for streamlining operations.
06—Continue